Exact Mass: 576.2656
Exact Mass Matches: 576.2656
Found 276 metabolites which its exact mass value is equals to given mass value 576.2656
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Anaerobilin
Bafetinib
Bafetinib is a tyrosine kinase inhibitor used to treat chronic myelogenous leukemia (CML), a cancer characterized by increased and unregulated growth of white blood cells in the bone marrow and the accumulation of these cells in the blood. Bafetinib is able to bind ABL with greater affinity than Imatinib (25-55 times more potent). It is therefore administered to patients with Imatinib resistance. Notably, Bafetinib is ineffective against the T315I mutation in BCR-ABL, and further research is necessary. C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
10-carboxy-5beta,14beta-dihydroxy-bufa-3,20,22-trienolid-5-O-beta-D-glucosid
16alpha-[(6-O-sulfo-beta-D-glucopyranosyl)oxy]pregn-5-ene-3beta,20-diol
(1S,4S,5S,6R,7R,8R,9R,10S)-1,6,8,15-tetra-acetoxy-9-benzoyloxy-4-hydroxy-dihydro-beta-agarofuran
1-O-benzoylsalannic acid methyl ester|1-O-decinnamoyl-1-O-benzoylohchinin
5-hydroxyarenobufagin-3-O-4?,6?-dideoxy-alpha-L-allohexopyranose|kalantuboside B
C30H40O11_Methyl 5,6-diacetoxy-10-hydroxy-2,4b,7,7,10a,12a-hexamethyl-12-methylene-1,4,8-trioxohexadecahydro-2H-naphtho[1,2-h]isochromene-2-carboxylate
methyl 5,6-diacetyloxy-10-hydroxy-2,4b,7,7,10a,12a-hexamethyl-12-methylidene-1,4,8-trioxo-4a,5,6,6a,9,10,10b,11-octahydronaphtho[1,2-h]isochromene-2-carboxylate
methyl 5,6-diacetyloxy-10-hydroxy-2,4b,7,7,10a,12a-hexamethyl-12-methylidene-1,4,8-trioxo-4a,5,6,6a,9,10,10b,11-octahydronaphtho[1,2-h]isochromene-2-carboxylate_major
Asp Arg Thr Trp
Asp Arg Trp Thr
Asp Thr Arg Trp
Asp Thr Trp Arg
Asp Trp Arg Thr
Asp Trp Thr Arg
Glu Arg Ser Trp
Glu Arg Trp Ser
Glu Ser Arg Trp
Glu Ser Trp Arg
Glu Trp Arg Ser
Glu Trp Ser Arg
Phe Phe Thr Tyr
Phe Phe Tyr Thr
Phe His His His
Phe Pro Gln Trp
Phe Pro Trp Gln
Phe Gln Pro Trp
Phe Gln Trp Pro
Phe Thr Phe Tyr
Phe Thr Tyr Phe
Phe Trp Pro Gln
Phe Trp Gln Pro
Phe Tyr Phe Thr
Phe Tyr Thr Phe
His Phe His His
His His Phe His
His His His Phe
Ile Met Gln Trp
Ile Met Trp Gln
Ile Gln Met Trp
Ile Gln Trp Met
Ile Trp Met Gln
Ile Trp Gln Met
Leu Met Gln Trp
Leu Met Trp Gln
Leu Gln Met Trp
Leu Gln Trp Met
Leu Trp Met Gln
Leu Trp Gln Met
Met Ile Gln Trp
Met Ile Trp Gln
Met Leu Gln Trp
Met Leu Trp Gln
Met Gln Ile Trp
Met Gln Leu Trp
Met Gln Trp Ile
Met Gln Trp Leu
Met Trp Ile Gln
Met Trp Leu Gln
Met Trp Gln Ile
Met Trp Gln Leu
Pro Phe Gln Trp
Pro Phe Trp Gln
Pro Gln Phe Trp
Pro Gln Trp Phe
Pro Trp Phe Gln
Pro Trp Gln Phe
Gln Phe Pro Trp
Gln Phe Trp Pro
Gln Ile Met Trp
Gln Ile Trp Met
Gln Leu Met Trp
Gln Leu Trp Met
Gln Met Ile Trp
Gln Met Leu Trp
Gln Met Trp Ile
Gln Met Trp Leu
Gln Pro Phe Trp
Gln Pro Trp Phe
Gln Trp Phe Pro
Gln Trp Ile Met
Gln Trp Leu Met
Gln Trp Met Ile
Gln Trp Met Leu
Gln Trp Pro Phe
Arg Asp Thr Trp
Arg Asp Trp Thr
Arg Glu Ser Trp
Arg Glu Trp Ser
Arg Ser Glu Trp
Arg Ser Trp Glu
Arg Thr Asp Trp
Arg Thr Trp Asp
Arg Trp Asp Thr
Arg Trp Glu Ser
Arg Trp Ser Glu
Arg Trp Thr Asp
Ser Glu Arg Trp
Ser Glu Trp Arg
Ser Arg Glu Trp
Ser Arg Trp Glu
Ser Val Trp Trp
Ser Trp Glu Arg
Ser Trp Arg Glu
Ser Trp Val Trp
Ser Trp Trp Val
Thr Asp Arg Trp
Thr Asp Trp Arg
Thr Phe Phe Tyr
Thr Phe Tyr Phe
Thr Arg Asp Trp
Thr Arg Trp Asp
Thr Trp Asp Arg
Thr Trp Arg Asp
Thr Tyr Phe Phe
Val Ser Trp Trp
Val Trp Ser Trp
Val Trp Trp Ser
Trp Asp Arg Thr
Trp Asp Thr Arg
Trp Glu Arg Ser
Trp Glu Ser Arg
Trp Phe Pro Gln
Trp Phe Gln Pro
Trp Ile Met Gln
Trp Ile Gln Met
Trp Leu Met Gln
Trp Leu Gln Met
Trp Met Ile Gln
Trp Met Leu Gln
Trp Met Gln Ile
Trp Met Gln Leu
Trp Pro Phe Gln
Trp Pro Gln Phe
Trp Gln Phe Pro
Trp Gln Ile Met
Trp Gln Leu Met
Trp Gln Met Ile
Trp Gln Met Leu
Trp Gln Pro Phe
Trp Arg Asp Thr
Trp Arg Glu Ser
Trp Arg Ser Glu
Trp Arg Thr Asp
Trp Ser Glu Arg
Trp Ser Arg Glu
Trp Ser Val Trp
Trp Ser Trp Val
Trp Thr Asp Arg
Trp Thr Arg Asp
Trp Val Ser Trp
Trp Val Trp Ser
Trp Trp Ser Val
Trp Trp Val Ser
Tyr Phe Phe Thr
Tyr Phe Thr Phe
Tyr Thr Phe Phe
POLY[4,4-METHYLENEBIS(PHENYL ISOCYANATE)-ALT-1,4-BUTANEDIOL/POLY(BUTYLENE ADIPATE)]
cyclooctane,(E)-5-hydroxy-2,2,6,6-tetramethylhept-4-en-3-one,ruthenium
Bafetinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
Albuterol sulfate
D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
[(2R,3R,4S,5R,6R)-2-[[(3S,4R,5R,8S,9S,10S,13R,14S,17R)-17-ethenyl-3-hydroxy-10-(hydroxymethyl)-13-methyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-4-yl]oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] hydrogen sulfate
(4Z,10Z,14E)-8,12-bis(2-carboxyethyl)-3,7,13,18-tetramethyl-1,2,17-trivinyl-23,24-dihydrobilin
(5S,6R,9R)-5-methoxy-N-(2-methoxyphenyl)-3,6,9-trimethyl-2-oxo-14-(pyrazine-2-carbonylamino)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-8-carboxamide
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-[4-(trifluoromethyl)anilino]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]cyclopropanecarboxamide
(5S,6R,9R)-5-methoxy-14-[(4-methoxyphenyl)sulfonylamino]-3,6,9-trimethyl-2-oxo-N-propan-2-yl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-8-carboxamide
(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-[[(3R,5R,8R,9S,10S,13S,14S,17S)-17-[(1S)-1-hydroxyethyl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4-sulfooxyoxane-2-carboxylic acid
ethyl (3s)-3-(acetyloxy)-3-[(1r,2r,5r,6r,7r,8s,10s,11s,14s)-11-(furan-3-yl)-8-hydroxy-5-(2-hydroxypropan-2-yl)-2,6,10-trimethyl-3,13-dioxo-12,15-dioxatetracyclo[8.5.0.0¹,¹⁴.0²,⁷]pentadecan-6-yl]propanoate
methyl 4-[(1s,2s,17s,19r)-12-hydroxy-8,8,21,21-tetramethyl-5-(3-methylbut-2-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4,6(11),9,12-tetraen-19-yl]-2-methylbut-2-enoate
9-{2-hydroxy-3-[(8-hydroxyheptadeca-1,9-dien-4,6-diyn-3-yl)oxy]-3-methylbutoxy}-4-methoxyfuro[3,2-g]chromen-7-one
(1s,2s,17s,19r)-12-hydroxy-19-[(2z)-4-hydroxy-3-methylbut-2-en-1-yl]-17-methoxy-8,8,21,21-tetramethyl-5-(3-methylbut-2-en-1-yl)-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4,6(11),9,12,15-pentaene-14,18-dione
(2e)-4-[(1r,2r,15s,16r,17r,19s)-12-hydroxy-16-methoxy-8,8,21,21-tetramethyl-5-(3-methylbut-2-en-1-yl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4,6(11),9,12-tetraen-19-yl]-2-methylbut-2-enal
(8s,21s)-16,27-dimethoxy-7,22-dimethyl-14,29,31-trioxa-7,22-diazaoctacyclo[19.9.3.2¹⁰,¹³.1⁴,³⁰.1¹⁵,¹⁹.0³,⁸.0²⁵,³³.0²⁸,³²]heptatriaconta-1(30),2,4(34),10,12,15(35),16,18,25,27,32,36-dodecaene
(8s)-16,27-dimethoxy-7,22-dimethyl-29,31-dioxa-7,22-diazaoctacyclo[19.9.3.1⁴,³⁰.1¹⁰,¹⁴.1¹⁵,¹⁹.0³,⁸.0²⁵,³³.0²⁸,³²]hexatriaconta-1(30),2,4(34),10,12,14(36),15(35),16,18,25,27,32-dodecaen-13-ol
12-hydroxy-16-methyl-15-(6-oxopyran-3-yl)-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-oxapentacyclo[9.7.0.0²,⁸.0⁵,⁷.0¹²,¹⁶]octadecane-2-carbaldehyde
15-Oxokaura-16-ene-2,3,6,7,11-pentaol pentaacetate
{"Ingredient_id": "HBIN001717","Ingredient_name": "15-Oxokaura-16-ene-2,3,6,7,11-pentaol pentaacetate","Alias": "NA","Ingredient_formula": "C30H40O11","Ingredient_Smile": "CC(=O)OC1CC2CC3(C1C4(CC(C(C(C4C(C3OC(=O)C)OC(=O)C)(C)C)OC(=O)C)OC(=O)C)C)C(=O)C2=C","Ingredient_weight": "576.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "458","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101421772","DrugBank_id": "NA"}